The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Challenge, 2013Functional Analysis of LRRK2 Phosphorylation in Human Dopaminergic Neurodegeneration
Objective/Rationale:
Although mutations in LRRK2 are the most common genetic cause of Parkinson’s disease (PD) known, the molecular mechanism is unclear. LRRK2 protein is phosphorylated (addition of a... -
Research Grant, 2013Kinase Activity in Lymphocytes
Objective/Rationale:
It has been suggested that the G2019S mutation in the LRRK2 gene leads to increased kinase (a type of enzyme) activity. Previous work has been conducted in cultured cells... -
Research Grant, 2013Phenylbutyrate for Alpha-synuclein Clearance from the Brain
Objective/Rationale:
In our previous research, we have discovered that a drug called phenylbutyrate can turn on a protective gene in the brain and can prevent Parkinson’s disease (PD) in... -
Rapid Response Innovation Awards, 2013The Role of Phosphorylation and Oligomerixation on Alpha-synuclein-induced Vesicle Rupture
Objective/Rationale:
The propagation of pathological alpha-synuclein in the central nervous system resembles a spreading viral infection. We have observed that alpha-synuclein can enter... -
Rapid Response Innovation Awards, 2013Novel Enzymatic Method for Improving Therapeutic Targeting of Dopaminergic Afferents
Objective/Rationale:
The presence of perineuronal nets (PNNs), structural elements associated with specific circuits within brain areas affected by Parkinson’s disease, may limit the... -
Research Grant, 2013Validation of the Movement Disorders Society Criteria for Mild Cognitive Impairment in Parkinson’s Disease
Objective/Rationale:
Dementia in Parkinson’s disease (PD) is a serious health issue and a major concern for many PD patients. Mild cognitive impairment (MCI) is considered a transitional...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.